TCM
VTYX

TCG Crossover Management’s Ventyx Biosciences VTYX Stock Holding History

TCG Crossover Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-316,195
Closed -$2.86M – 53
2025
Q4 		$2.86M Hold
316,195
– – 0.09% 42
2025
Q3 		$983K Hold
316,195
– – 0.05% 40
2025
Q2 		$677K Hold
316,195
– – 0.08% 35
2025
Q1 		$364K Hold
316,195
– – 0.05% 36
2024
Q4 		$692K Hold
316,195
– – 0.07% 37
2024
Q3 		$689K Hold
316,195
– – 0.06% 35
2024
Q2 		$730K Sell
316,195
-499,529
-61% -$2.08M 0.08% 31
2024
Q1 		$4.49M Hold
815,724
– – 0.35% 31
2023
Q4 		$2.01M Hold
815,724
– – 0.22% 28
2023
Q3 		$28.3M Hold
815,724
– – 4.17% 12
2023
Q2 		$26.8M Hold
815,724
– – 4.39% 10
2023
Q1 		$27.3M Buy
815,724
+28,493
+4% +$1.11M 5.33% 6
2022
Q4 		$25.8M Buy
+787,231
New +$23.3M 4.56% 9

Other funds holding VTYX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TCG Crossover Management's VTYX Position: Q1 2026 in Review

TCG Crossover Management sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 316,195 shares — an estimated $2.86M sold.

TCG Crossover Management first reported a position in VTYX in Q4 2022 and held it in 13 quarters. The position peaked at $28.3M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.

  • TCG Crossover Management reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
  • TCG Crossover Management sold 316,195 Ventyx Biosciences shares in Q1 2026, an estimated $2.86M.
  • TCG Crossover Management first reported a position in Ventyx Biosciences in Q4 2022 and held it in 13 quarters.
  • TCG Crossover Management's Ventyx Biosciences position peaked at $28.3M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.